冠状动脉内注射替罗非班治疗冠状动脉介入中无复流的疗效观察

目的观察冠状动脉内注射替罗非班对冠状动脉介入(PCI)术中无复流的疗效。方法 21例PCI中出现无复流患者,冠脉内注入替罗非班注射液12μg/kg负荷量,0.15μg/(kg·min)静脉维持36h,比较给药前与冠脉内给药后10min冠状动脉造影的校正后的计帧数(CTFC)、TIMI血流分级。结果给药前与给药后校正后的计帧数(CTFC)由(62.42±11.60)帧降至(28.62±8.60)帧,前后比较差异有统计学意义(P<0.01);给药前后TIMI血流变化比较,显效13例(61.9%),有效7例(33.3%),总有效率达95.2%。结论冠状动脉内注射替罗非班治疗PCI术中无复流现象有效。

Therapeutic effects of tirofiban on patients with no-reflow during PCI

Objective To observe the therapeutic effects of tirofiban on patients with no-reflow during percutaneous coronary intervention (PCI) .Methods Twenty-three patients with no-reflow phenomenon were injected tirofiban (12 μg/kg) via coronary artery during PCI,and intravenously administered tirofiban for 36 hours (0.15 μg/kg/min) .Corrected TIMI frame count (CTFC) and TIMI flow grade were compared between before and after (10 min) intracoronary application of tirofiban.Results CTFC was reduced from 62.42±11.60 down to 28.62±8.60,with a significant difference (P<0.01) .TIMI flow grade was improved in 7 cases and effective in 13 cases,with a effectiveness rate of 95.2% .Conclusion Tirofiban has definite effect on patients with no-reflow during PCI.